baxter report outlook
updat forecast estim feb
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research feb
estim feb
price data feb
rate updat feb
currenc amount express
valuat growth profit
methodolog valu compani
baxter face number near-term challeng follow
spin-off baxalta think growth remain rel
stabl go forward manag attempt boost
profit remain lower close peer like
freseniu hospira acquir carefus acquir
becton dickinson thank compani competit
advantag dialysi hospit market give decent
odd margin expans gain come year
number factor depress baxter histor cash flow
recent result offer evid futur margin improv
gener competit brand oncolog drug cyclophosphamid
end currenc headwind dis-synergi
baxalta split regulatori manufactur issu pension
expens adjust weigh earn beyond
mostli temporari issu think manag restructur
effort continu improv profit thank synergi
gambro acquisit optim manufactur
distribut oper exit unprofit busi line
refocus new product launch higher-margin segment
nutrit anesthet biosurgeri meanwhil capit
expenditur declin recent level compani
work regulatori issu expand manufactur
capac solut product
emerging-market exposur healthi demand mani
long-term growth baxter compani sale
intern market emerg market make
impress sale nearli one third new baxter revenu
renal segment particularli expos intern
market boost compani growth trajectori thank
rise global rate diabet obes high blood pressur
increas global demand dialysi sustain strong dialysi
market growth especi true baxter periton
dialysi oper global market clinic infrastructur
typic match unit state europ
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
segment renal segment sale includ hemodialysi
periton dialysi product integr pharmaci solut sale
includ nutrit inject drug compound servic iv pump
solut make fluid system segment sale
biosurg suppli anesthet gase constitut surgic care
segment sale contract manufactur servic round
roughli remain sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
baxter report outlook
dont expect major chang fair valu estim
narrow-moat baxter compani fourth-quart
result mostli match expect exclud
currenc cyclophosphamid exit product categori
quarterli revenu climb includ previous
estim million top-lin ep hit
hurricane-rel manufactur issu puerto rico
primarili drove declin adjust
oper margin last year baxter continu
navig number temporari crosswind relat
hurrican cyclophosphamid still see
enhanc margin improv think
puerto rico manufactur issu address
end first quarter base manag
although need make adjust
forecast stack close manag outlook
adjust ep near billion
free cash flow outlook includ revenu
growth includ currenc benefit along
basi point oper margin expans
incorpor manag expect increas
competit cyclophosphamid year
subtract top-lin growth nearli basi
point oper margin new report structur
solut advanc surgeri sealant nutrit
post high- mid-single-digit growth
constant-curr basi baxter estim also see
slight tax rate benefit recent legisl pass
unit state
regardless on-going cyclophosphamid headwind
still anticip manag meet long-term margin
expans goal thank continu focu product
categori oper effici improv thank
baxter clean balanc sheet also anticip tuck-in
acquisit recent clari gener inject
deal continu play role compani
develop instanc outlook
includ recent announc acquisit hemostat
sealant product close
first half year repres million
sale annual basi
valuat growth profit jan
rais fair valu estim baxter per
share primarili slightli increas
near-term growth forecast adjust time valu
money sinc last updat fair valu estim
impli price-to-earnings multipl believ
potenti healthi margin expans come
year justifi current fair valu estim
think baxter long-term revenu growth potenti
near led larg higher growth opportun renal
nutrit biosurgeri segment togeth
constitut nearli consolid revenu expect
low- mid-single-digit growth baxter
segment gener competit cyclophosphamid
sale nearli million currenc
headwind two largest constraint
growth sinc beyond think revenu growth
return mid-single-digit rang addit
focus higher-growth segment new product
launch baxter intern emerging-market
exposur support compani long-term growth outlook
baxter move beyond mostli temporari headwind
think manag focu control cost
boost profit aspect busi lead
nearli basi point margin expans next
five year forecast lead adjust
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
growth factor push adjust oper margin
nearli basi point base-cas
forecast return capit eventu climb
scenario impli fair valu estim per
fair valu estim per share bear-cas
forecast incorpor slower growth less margin
expans greater market competit less price
power keep growth report segment
low-single-digit addit forecast manag
fall well margin expans goal adjust
oper margin reach return capit
remain mid-teen scenario
think economi scale support narrow moat
baxter modest switch cost baxter
segment like infus pump anesthet dialysi
consider diversif follow baxalta spin-off
think retain suffici exposur varieti
oligopolist med tech market fairli high barrier
entri -- due larg up-front capit cost achiev
necessari scale regulatori requir -- diminish
oper risk sustain return cost
capit substanti portion compani sale come
commodifi product dialysi solut
dialyz inject drug iv solut offer
littl price power leav us hesit award wide
econom moat rate time
think approxim baxter oper
measur revenu hemodialysi periton dialysi
parenter nutrit iv pump solut biosurgeri
anesthet possess competit advantag worthi
econom moat tend view baxter
oper margin reach nearli long term
also think capit spend percentag sale
fall come year effort expand solut
manufactur capac draw close
profit combin lower capit spend
push free cash flow close billion
estim assumpt result return capit
recov high-teen estim baxter cost
equiti
sinc baxter fairli well diversifi particip
rel stabl market think compani
emerg market
bull-cas scenario assum new product launch
favor price condit greater market
high-single-digit revenu growth across report
segment lead averag annual growth
also forecast manag exceed initi cost-sav
streamlin manufactur
distribut effort success transit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
inject gener drug -- fewer competit
advantag nonetheless share signific synergi
baxter manufactur process leverag
hospit salesforc help contribut compani
baxter major player global dialysi equip
integr busi largest dialysi servic
provid equip manufactur give competit
edg baxter take second place larger
hemodialysi product market absolut domin
smaller periton market approxim
share respect estim economi scale
vital market especi manufactur
commoditylik dialysi consum like dialyz
dialysi solut acquisit gambro also
made baxter formid competitor ad extra
scale expand product catalog
global iv pump market baxter particip
concentr oligopoli includ carefus bought
hospira bought braun
freseniu infus pump long life
approxim five-year replac cycl hospit
often stick familiar brand keep switch
network softwar help devic becom
embed custom oper hospit seek lower
medic administr cost increas drug safeti
devic correspond softwar integr
hospit infrastructur transfer competit
recur revenu stream higher-margin dedic
consum hospira baxter freseniu also
among primari manufactur iv solut use
infus pump includ pump solut
estim baxter global iv market share near
baxter anesthet franchis one profit
segment thank high barrier entri strong
switch cost baxter competitor offer
supran isofluran sevofluran face gener
competit primarili piram
desfluran brand supran like soon face
gener competit patent expir late
howev complex manufactur inhal
drug along proprietari vapor hardwar instal
manufactur help keep barrier entri switch
cost higher convent drug translat
low level competit estim baxter market
share segment
think necessari economi scale product
complex support strong competit advantag
baxter parenter nutrit biosurgeri oper
among compani highest-margin segment
along anesthet similar baxter solut
higher complex
entri higher common tube-f nutrit
product surgic sealant tisseel floseal make
baxter major player biosurgeri market along
primari competitor johnson johnson baxter ad
franchis time apatech synovi
acquisit respect enhanc
bone fusion soft tissu repair capabl
think baxter larg presenc sever stabl
oligopoli major revenu base lead
stabl moat baxter primarili particip
predict market
evolut avoid potenti risk disrupt
biotech product spun baxalta busi new
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
product launch includ new dialysi infus
pump enabl baxter broaden market
offer stay ahead competit preserv price
power on-going invest boost solut
manufactur capac preserv compani
scale advantag part margin expans goal
imagin manag invest capit
moat-worthi higher-margin biosurgeri nutrit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
obaxt typic lead competitor often take
number-on -two spot mani market
compet dialysi equip parenter
nutrit biosurgeri anesthet gase
product launch refocus capit higher-
margin product line de-emphasize unprofit
segment enhanc baxter profit
oemerg market prime sourc growth
mani baxter product especi dialysi
product nutrit solut
obaxt profit appear
peer could make margin gain difficult
come year
oalthough mani baxter product essenti
medic care patient health mani
compani product commod littl
owhil baxter acquisit gambro strengthen
firm posit dialysi market gambro
histor growth flat baxter goal
acceler organ gambro-sourc growth
next year could prove lofti
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
baxter retain rel good financi health follow
spin-off baxalta baxter use cash spin-off
retain stake baxalta pay debt reduc
underfund pension tender exist share long
manag continu improv profit
cash flow anticip leverag ratio improv
current expect baxter retain net debt/adjust ebitda
along comfort interest coverag ratio
manag target dividend pay-out ratio
adjust net incom share repurchas
small acquisit also like remain factor capit
think baxter shed potenti riskier asset
baxalta spin-off leav well-diversifi compani
particip market littl risk disrupt
competit threat gener competit cyclophosphamid
late major effect profit
sinc baxter major patent
protect drug issu recur theme
investor despit modest likelihood futur gener
competit baxter inhal anesthet portfolio
think manufactur market barrier entri
product categori preserv baxter market share
regulatori issu remain concern busi
includ previou warn letter food drug
administr view current problem
major threat busi baxter face major
setback past howev includ colleagu
infus pump recal think poor manag asset
compani inabl improv profit
long term may one greater risk healthi return
futur
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
almeida previous chairman ceo covidien
join baxter octob replac longtim
chairman ceo robert parkinson jr baxalta
spin-off parkinson focus invest baxter pipelin
view posit sign even though payoff
mani pipelin invest remain unclear
improv compani profit appear
almeida greatest challeng somewhat
concern issu previous
address refocus profit busi
line streamlin manufactur distribut
oper see baxter lag profit
potenti sign poor manag qualiti place
onu almeida team boost result
better-than-expect perform compani
show earli sign success manag margin
improv initi manag commit
pay rel healthi dividend baxter seem
reason imagin probabl number
extern intern invest opportun could
baxter intent expand gener inject drug
far capit alloc decis seem reason
opinion fortun
repres date owner name posit common share held report holder issuer
new york mellon corp
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
baxter year-end perform track despit
baxter report growth adjust oper
margin third quarter keep
perform mostli line expect despit
million top line ep headwind expect
fourth quarter hurrican impact manufactur
site puerto rico manag slightli rais year-
end adjust ep outlook base part
cyclophosphamid perform lower tax rate
anticip chang fair valu estim
narrow-moat rate compani incorpor
adjust model think on-going
margin expans effort support healthi earn
growth still think share look bit overvalu
continu bolster confid manag abil
drive oper margin expans think firm
abil exceed manag oper margin goal
prove difficult meanwhil baxter top-lin
growth -- benefit time million
contract settlement million contribut
clari acquisit quarter -- remain subdu thank
categori
manag effort retrench less profit
categori manag expect suppli issu
hurrican partial help temporari
import site fda allevi product
shortfal diminish first quarter next year
clari acquisit help bolster growth
integr pharmaci segment expect long-
term increas competit gener inject
market manufactur pursu complex formul
limit upsid potenti asset
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
equival
net properti plant equip
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
